Methods for screening compounds for bactericidal activity and for determining the sensitivity of bacterial samples
US-12595504-B2 · Apr 7, 2026 · US
This page is not indexed by search engines while we improve data quality.
Univ Paris Saclay — Physics
Univ Paris Saclay holds 91 patents in Physics, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Univ Paris Saclay |
| Technology | Physics |
| Patents in slice | 91 |
| Recent patents in slice | 65 |
| First year | 2020 |
| Last year | 2026 |
Representative patents
Notable publications linking Univ Paris Saclay to Physics.
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Recent filings
Latest patents from Univ Paris Saclay in Physics.
Methods for screening compounds for bactericidal activity and for determining the sensitivity of bacterial samples
US-12595504-B2 · Apr 7, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Related pages
Navigate to parent entity pages.